Development of a preliminary composite disease activity index in psoriatic arthritis

被引:164
作者
Mumtaz, Aizad
Gallagher, Phil
Kirby, Brian [2 ]
Waxman, Robin [3 ]
Coates, Laura C. [3 ]
Veale, Douglas J.
Helliwell, Philip [3 ]
FitzGerald, Oliver [1 ]
机构
[1] St Vincents Univ Hosp, Univ Coll Dublin, Dublin Acad Hlth Care, Bone & Joint Unit,Dept Rheumatol, Dublin 4, Ireland
[2] St Vincents Univ Hosp, Dept Dermatol, Dublin 4, Ireland
[3] Univ Leeds, Leeds Inst Mol Med, Sect Musculoskeletal Dis, Leeds, W Yorkshire, England
关键词
QUALITY-OF-LIFE; ANKYLOSING-SPONDYLITIS; CLASSIFICATION; RELIABILITY; ADALIMUMAB; PLACEBO;
D O I
10.1136/ard.2010.129379
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To develop a preliminary composite psoriatic disease activity index (CPDAI) for psoriasis and psoriatic arthritis. Methods Five domains were assessed and specific instruments were employed for each domain to determine the extent of domain involvement and the effect of that involvement on quality of life/function. Disease activity for each domain was then graded from 0 to 3 giving a CPDAI range of 0-15. Patient and physician global disease activity measures were also recorded and an independent physician was asked to indicate if treatment change was required. Bivariate correlation analysis was performed. Factor, tree analysis and standardised response means were also calculated. Results Significant correlation was seen between CPDAI and both patient (r= 0.834) and physician (r = 0.825) global disease activity assessments (p = 0.01). Tree analysis revealed that 96.3% of patients had their treatment changed when CPDAI values were greater than 6; no patient had their treatment changed when CPDAI values were less than 5. Conclusion CPDAI correlates well with patient and physician global disease activity assessments and is an effective tool that clearly distinguishes those who require a treatment change from those who do not.
引用
收藏
页码:272 / 277
页数:6
相关论文
共 30 条
  • [11] GARRETT S, 1994, J RHEUMATOL, V21, P2286
  • [12] Consensus exercise on domains in psoriatic arthritis
    Gladman, DD
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 113 - 114
  • [13] Gladman DD, 2004, J RHEUMATOL, V31, P1126
  • [14] GLADMAN DD, 1990, J RHEUMATOL, V17, P62
  • [15] GLADMAN DD, 1993, CLIN INVEST MED, V16, P1
  • [16] Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritis
    Healy, Paul J.
    Helliwell, Philip S.
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2008, 59 (05): : 686 - 691
  • [17] Translating the science of quality of life into practice: What do dermatology life quality index scores mean?
    Hongbo, Y
    Thomas, CL
    Harrison, MA
    Salek, MS
    Finlay, AY
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 125 (04) : 659 - 664
  • [18] A classification study of clinical subsets in an inception cohort of early psoriatic peripheral arthritis - 'DIP or not DIP revisited'
    Kane, D
    Stafford, L
    Bresnihan, B
    FitzGerald, O
    [J]. RHEUMATOLOGY, 2003, 42 (12) : 1469 - 1476
  • [19] A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience
    Kane, D
    Stafford, L
    Bresnihan, B
    FitzGerald, O
    [J]. RHEUMATOLOGY, 2003, 42 (12) : 1460 - 1468
  • [20] Evaluation of Ankylosing Spondylitis Spinal Mobility Measurements in the Assessment of Spinal Involvement in Psoriatic Arthritis
    Luis Fernandez-Sueiro, Jose
    Willisch, Alfredo
    Pertega-Diaz, Sonia
    Pinto Tasende, Jose Antonio
    Fernandez-Lopez, Carlos
    Galdo, Fausto
    Javier Blanco, Francisco
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2009, 61 (03): : 386 - 392